BrainChild Bio

Tomorrow is Rare Disease Day, and we stand with children and families facing one of the most devastating rare pediatric cancers: diffuse intrinsic pontine glioma (DIPG). DIPG is an aggressive brain tumor that primarily affects children. Despite decades of research, outcomes have remained largely unchanged; there are still no approved therapies that meaningfully alter the course of this disease. We are advancing innovative, cell-based immunotherapy approaches designed specifically for children with DIPG — with the goal of delivering targeted treatment directly where it is needed most. On #RareDiseaseDay, we honor the courage of patients and families, the dedication of clinicians and researchers, and the collective commitment to changing what is possible for children diagnosed with rare, life-threatening cancers. #RareDiseaseDay2026 #DIPG #PediatricCancer #Immunotherapy #ChildhoodCancer

Recognizing #WorldBrainTumorDay yesterday, we honor the strength, spirit, and stories of children and families facing unimaginable challenges. One of them is Gavin, a bright, curious, and courageous 7-year-old who is living with DIPG (diffuse intrinsic pontine glioma), one of the most devastating pediatric brain tumors. Gavin is enjoying life as a kindergarten kid, after receiving an investigational CAR T-cell therapy in a clinical trial. Gavin is able to be much more than his diagnosis. He’s a Lego builder, a joke teller, and a light in every room he enters. At BrainChild Bio, Gavin reminds us why we do this work. His fight fuels our mission to develop a CAR T therapy for cancers of the CNS, including DIPG. Our lead drug candidate, BCB-276, an autologous B7-H3 CAR T-cell therapy is advancing towards a single pivotal Phase 2 clinical trial. #DIPGAwareness #BrainTumorAwareness #PediatricCancer #DefeatDIPG #BTSM #WBTD #BrainTumorDay Read Gavin’s story in our latest blog:

Receiving two designations, RMAT and Breakthrough Therapy, from independent reviews within FDA further validates our positive #CARTcells clinical results to date and the urgent need for a treatment for diffuse intrinsic pontine glioma #DIPG. We are moving ahead to initiate the pivotal trial by the end of 2025 to bring new treatments for CNS brain tumors in children and adults. #BrainChildTargetsCNSCancer https://lnkd.in/eafgRvkn

At BrainChild Bio, we’re positioned to initiate a pivotal clinical trial for an incurable brain cancer, supported by promising Phase 1 results showing an overall survival benefit in children with brain tumors treated with our approach: an autologous CAR T-cell therapy that targets the immune checkpoint B7-H3. Our primary focus is a monster known as diffuse intrinsic pontine glioma (DIPG), a fast-growing type of brain tumor that starts in the part of the brain stem called the pons. Our plan is to then expand our technology platform to adult brain tumors. Our next generation CAR T-cell therapy for tumors of the CNS, called BCB-276, is built on years of pioneering CAR T research at Seattle Children’s, which launched BrainChild Bio. Now, we have a potentially accelerated clinical path for BCB-276 supported by the promising CAR T-cell therapy safety and efficacy data from the Phase 1 clinical trial conducted by Seattle Children’s in pediatric brain tumors, including DIPG, published in Nature Medicine earlier this year. Read more in our blog post:

Breakthrough Therapy designation gives us the possibility to accelerate the development path for BCB-276 as a CAR T-cell therapy that can potentially transform the treatment of diffuse intrinsic pontine glioma (#DIPG), an incurable brain tumor. Our pioneering #CARTcells approach opens a new paradigm for treating other CNS brain tumors in children and adults. Read more: https://lnkd.in/e-8jdETb